BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol. 2011;2011:214013. [PMID: 21826145 DOI: 10.1155/2011/214013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Bonroy C, Smith V, Deschepper E, De Keyser F, Devreese K. Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening. J Rheumatol 2016;43:247-9. [DOI: 10.3899/jrheum.150105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Dunne JV, van Eeden SF, Keen KJ. L-selectin and skin damage in systemic sclerosis. PLoS One 2012;7:e44814. [PMID: 23028631 DOI: 10.1371/journal.pone.0044814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hohenstein B, Bornstein S, Aringer M. Immunoadsorption for connective tissue disease. Atherosclerosis Supplements 2013;14:185-9. [DOI: 10.1016/j.atherosclerosissup.2012.10.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 McLean-Tooke A, Moore I, Lake F. Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges. Clin Transl Immunology 2019;8:e1086. [PMID: 31709050 DOI: 10.1002/cti2.1086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
5 Zhu L, Chung MP, Gagne L, Guo HH, Guenther Z, Li S, Jacobs S, Morisset J, Mooney JJ, Raj R, Chung L. Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease. ACR Open Rheumatol 2021;3:3-7. [PMID: 33274857 DOI: 10.1002/acr2.11210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 De Langhe E, Lories R. Fibrogenesis, novel lessons from animal models. Semin Immunopathol. 2015;37:565-574. [PMID: 26141608 DOI: 10.1007/s00281-015-0510-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016;18:118. [PMID: 27208972 DOI: 10.1186/s13075-016-1017-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
8 Klavdianou K, Liossis SN, Sakkas L, Daoussis D. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 2017;46:430-8. [PMID: 27670695 DOI: 10.1016/j.semarthrit.2016.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 [DOI: 10.5499/wjr.v3.i2.9] [Reference Citation Analysis]
10 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
11 Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis 2021. [PMID: 34272836 DOI: 10.1002/iid3.475] [Reference Citation Analysis]
12 Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88. [PMID: 23557513 DOI: 10.1186/1741-7015-11-88] [Cited by in Crossref: 137] [Cited by in F6Publishing: 105] [Article Influence: 17.1] [Reference Citation Analysis]
13 Lanteri A, Sobanski V, Langlois C, Lefèvre G, Hauspie C, Sanges S, Lambert M, Morell-dubois S, Hatron P, Hachulla E, Launay D, Dubucquoi S. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmunity Reviews 2014;13:974-80. [DOI: 10.1016/j.autrev.2014.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
14 Pai S, Hsu V. Are there risk factors for scleroderma-related calcinosis? Mod Rheumatol 2018;28:518-22. [PMID: 28722530 DOI: 10.1080/14397595.2017.1349594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;46:625-31. [PMID: 27839742 DOI: 10.1016/j.semarthrit.2016.10.003] [Cited by in Crossref: 102] [Cited by in F6Publishing: 87] [Article Influence: 20.4] [Reference Citation Analysis]
16 Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822-9. [PMID: 22221908 DOI: 10.1016/j.semarthrit.2011.11.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
17 McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 2014;23:183-98. [PMID: 24261610 DOI: 10.1517/13543784.2014.848852] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
18 Zeineddine N, Khoury LE, Mosak J. Systemic Sclerosis and Malignancy: A Review of Current Data. J Clin Med Res 2016;8:625-32. [PMID: 27540435 DOI: 10.14740/jocmr2606w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
19 Colletti M, Galardi A, De Santis M, Guidelli GM, Di Giannatale A, Di Luigi L, Antinozzi C. Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components? Int J Mol Sci 2019;20:E4337. [PMID: 31487964 DOI: 10.3390/ijms20184337] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
20 Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C. Systemic sclerosis and cryoglobulinemia: Our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmunity Reviews 2013;12:1058-63. [DOI: 10.1016/j.autrev.2013.06.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
21 Karampitsakos T, Vraka A, Bouros D, Liossis SN, Tzouvelekis A. Biologic Treatments in Interstitial Lung Diseases. Front Med (Lausanne) 2019;6:41. [PMID: 30931306 DOI: 10.3389/fmed.2019.00041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
22 Arts MR, Baron M, Chokr N, Fritzler MJ, Servant MJ; Canadian Scleroderma Research Group (CSRG). Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor. PLoS One 2014;9:e100035. [PMID: 24927197 DOI: 10.1371/journal.pone.0100035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]